Your shopping cart is empty!
Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
Catalog: | HY-P9908 |
Brand: | MCE |
CAS: | 331731-18-1 |
MDL | - |
---|---|
Molecular Weight | 145425.42 |
Molecular Formula | - |
SMILES | [Adalimumab] |
Adalimumab is a human monoclonal IgG1 antibody targeting tumour necrosis factor α ( TNF-α ).
TNF-α [1]
Treatment of HUVECs with Adalimumab for up to 12 hours shows no adverse effect on their cell viability, even with a 10-fold higher concentration of Adalimumab than used in this study [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
The elimination half-life (t 1/2 ) of Adalimumab is long (~20 days) [1] . The enriched fluorescent-labelled adalimumab is observed mainly in major Oil red O-positive lesions documenting good tissue penetration of the drug into the atherosclerotic plaque, without background fluorescence of the vessel wall after vehicle control injection into hypercholesterolemic Ldlr -/- mice [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
NCT Number | Sponsor | Condition | Start Date | Phase |
---|---|---|---|---|
NCT03955861 | Belfast Health and Social Care Trust|British Medical Association|Psoriasis and Psoriatic Arthritis Alliance|Queen´s University, Belfast |
Psoriatic Arthritis|Psoriasis|Enthesitis
|
February 14, 2019 | |
NCT00595413 | EMD Serono|Merck KGaA, Darmstadt, Germany |
Rheumatoid Arthritis
|
September 2007 | Phase 2 |
NCT00235859 | Abbott|Eisai Limited |
Rheumatoid Arthritis
|
July 2003 | Phase 3 |
NCT04808739 | Fundació Institut de Recerca de l´Hospital de la Santa Creu i Sant Pau |
Psoriasis
|
June 1, 2020 | |
NCT00055497 | Abbott |
Crohn´s Disease
|
August 2002 | Phase 3 |
NCT03273192 | Cinnagen |
Bioequivalence|Phase 1
|
October 22, 2016 | Phase 1 |
NCT03254810 | Synermore Biologics Co., Ltd. |
Arthritis, Rheumatoid
|
September 26, 2017 | Phase 1 |
NCT03885713 | Fundación de Investigación Biomédica - Hospital Universitario de La Princesa |
Inflammatory Bowel Diseases|Crohn Disease|Ulcerative Colitis
|
September 10, 2019 | Phase 4 |
NCT00497614 | University Hospital, Tours |
Rheumatoid Arthritis
|
May 2006 | Not Applicable |
NCT00827996 | Florida Academic Dermatology Centers|Abbott |
Hidradenitis Suppurativa
|
February 2007 | Phase 2 |
NCT04725422 | Seattle Children´s Hospital|Boston Children´s Hospital, Boston, MA, USA|Hospital for Special Surgery, New York City, NY, USA|Joseph M Sanzari Children´s Hospital, Hackensack University Medical Center, Hackensack, NJ, USA|Riley Children´s Hospital, Indianapolis, IN, USA|University of North Carolina, Chapel Hill, NC, USA|Royal Children´s Hospital, Melbourne, Australia|Hacettepe University, Ankara, Turkey|Bambino Gesù Children´s Hospital, Rome, Italy|University of British Columbia, Vancouver, BC, Canada|Meyer Children´s Hospital, Florence, Italy|Mansoura University |
Chronic Nonbacterial Osteomyelitis|Chronic Recurrent Multifocal Osteomyelitis
|
August 1, 2018 | |
NCT02471118 | Canadian Research & Education in Arthritis|AbbVie |
Osteoarthritis, Knee
|
March 2015 | Phase 2 |
NCT00972218 | University of Alberta|Abbott |
Spondyloarthritis|Crohn´s Disease
|
July 2009 | Phase 4 |
NCT01243671 | AbbVie (prior sponsor, Abbott)|Eisai Co., Ltd.|AbbVie |
Intestinal Behçet´s Disease
|
October 2010 | Phase 3 |
NCT03221621 | Erasmus Medical Center|Prothya Biosolutions |
Hidradenitis Suppurativa
|
July 31, 2018 | Phase 4 |
NCT01174186 | Regionshospitalet Silkeborg|Abbott|Medtronic - MITG|Central Denmark Region |
Spondyloarthritis|Enterocolitis
|
October 2010 | Phase 4 |
NCT00647491 | Abbott|Eisai Limited |
Rheumatoid Arthritis
|
February 2004 | Phase 2|Phase 3 |
NCT01119859 | Hoffmann-La Roche |
Rheumatoid Arthritis
|
May 2010 | Phase 4 |
NCT00385736 | Abbott |
Ulcerative Colitis
|
November 2006 | Phase 3 |
NCT05414201 | AbbVie |
Non-infectious Intermediate Posterior- or Pan-uveitis
|
July 7, 2022 | Phase 4 |
NCT00525902 | Oregon Health and Science University|University of Illinois at Chicago|The Cleveland Clinic |
Uveitis
|
January 2008 | Phase 2 |
NCT02745080 | Novartis Pharmaceuticals|Novartis |
Psoriatic Arthritis
|
April 3, 2017 | Phase 3 |
NCT00274352 | Pariser, Robert J., M.D.|Abbott|Virginia Clinical Research, Inc. |
Sarcoidosis
|
September 2006 | Phase 2 |
NCT01197144 | Karolinska Institutet|Abbott|Swedish Foundation for Strategic Research|The Swedish Research Council |
Arthritis, Rheumatoid|Pain|Fatigue
|
October 2010 | Not Applicable |
NCT00477893 | Glostrup University Hospital, Copenhagen|Abbott |
Spondyloarthritis
|
February 2006 | Phase 4 |
NCT00514982 | National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) |
Hermanski-Pudlak Syndrome|Colitis|Cytokines|Lymphocytes|Drug Evaluation
|
August 7, 2007 | Phase 2 |
NCT00736983 | Foundation for Liver Research |
Crohn´s Disease With Perianal Fistulas
|
September 2008 | Phase 3 |
NCT01295814 | ICStudy, LLC|Abbott |
Interstitial Cystitis
|
March 2011 | Phase 3 |
NCT04514796 | Samsung Bioepis Co., Ltd. |
Healthy
|
August 13, 2020 | Phase 1 |
NCT02489760 | Chung Shan Medical University |
Ankylosing Spondylitis
|
July 2008 | Phase 4 |
NCT01986127 | Sara Varea|Hospital Clinic of Barcelona|Fundacion Clinic per a la Recerca Biomédica |
Crohn´s Disease
|
February 14, 2014 | Phase 3 |
NCT00603993 | Abbott|Abbott Japan Co.,Ltd|Eisai Co., Ltd. |
Rheumatoid Arthritis
|
March 2006 | Phase 3 |
NCT00730717 | Wright State University|Stanford University|Wake Forest University Health Sciences |
Pyoderma Gangrenosum
|
May 2009 | Phase 2 |
NCT03789292 | Celltrion |
Rheumatoid Arthritis
|
November 26, 2018 | Phase 3 |
NCT00233558 | Abbott |
Rheumatoid Arthritis
|
June 2005 | Phase 4 |
NCT01264770 | AstraZeneca |
Rheumatoid Arthritis
|
January 2011 | Phase 2 |
NCT05299242 | University of Oxford|National Institute for Health Research, United Kingdom|180 Life Sciences |
Frozen Shoulder
|
May 27, 2022 | Phase 2|Phase 3 |
NCT01231321 | Abbott |
Rheumatoid Arthritis
|
December 2007 | Phase 3 |
NCT04655807 | Janssen Research & Development, LLC |
Crohn Disease
|
March 3, 2021 | Phase 2 |
NCT01877668 | Pfizer |
Psoriatic Arthritis
|
January 20, 2014 | Phase 3 |
NCT02332356 | Tokyo Medical and Dental University |
Crohn Disease
|
September 2014 | Phase 3 |
NCT00870467 | Abbott|Eisai Co., Ltd. |
Rheumatoid Arthritis
|
March 2009 | Phase 3 |
NCT02480153 | Pfizer |
Rheumatoid Arthritis
|
June 25, 2015 | Phase 3 |
NCT03110094 | Rennes University Hospital |
Rheumatoid Arthritis
|
March 13, 2017 | Not Applicable |
NCT05105347 | Peking Union Medical College Hospital |
Uveitis
|
November 10, 2021 | Phase 4 |
NCT00735787 | Abbott |
Psoriasis
|
August 2008 | Phase 4 |
NCT00235872 | Abbott|Abbott Japan Co.,Ltd|Eisai Co., Ltd. |
Rheumatoid Arthritis
|
August 2004 | Phase 3 |
NCT02850965 | Boehringer Ingelheim |
Psoriasis
|
August 17, 2016 | Phase 3 |
NCT01808118 | AbbVie |
Axial Spondyloarthritis
|
April 16, 2013 | Phase 3 |
NCT01500278 | UCB Pharma SA|Parexel|UCB Pharma |
Rheumatoid Arthritis
|
December 2011 | Phase 4 |
NCT00296894 | University Hospital, Ghent |
Erosive Osteo-Arthritis
|
May 2006 | Phase 2 |
NCT01562951 | Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa|Abbott|TFS Trial Form Support |
Crohn´s Disease|Mucosal Inflammation
|
October 2012 | Phase 3 |
NCT02150473 | Heinrich-Heine University, Duesseldorf|Abbott |
Rheumatoid Arthritis
|
October 2014 | Phase 3 |
NCT04132388 | Wake Forest University Health Sciences |
Hidradenitis Suppurativa
|
August 20, 2020 | Phase 4 |
NCT00814866 | Université de Sherbrooke|Abbott |
Rheumatoid Arthritis
|
September 2008 | Not Applicable |
NCT04870203 | University Hospital, Bordeaux|Eli Lilly and Company|Biogen|Ministry for Health and Solidarity, France |
Rheumatoid Arthritis
|
July 15, 2021 | Phase 3 |
NCT03849404 | Alvotech Swiss AG |
Plaque Psoriasis
|
February 20, 2019 | Phase 3 |
NCT00291915 | Goupe d´Etudes et de Recherche Clinique En Rhumatologie |
Rheumatoid Arthritis|Arthritis
|
May 2004 | Phase 4 |
NCT03607903 | Centre for Human Drug Research, Netherlands|Leiden University Medical Center|Leiden Academic Center for Drug Research, the Netherlands |
Pain|Injection Site
|
July 11, 2018 | Phase 1|Phase 2 |
NCT04255134 | St George´s, University of London |
Rheumatoid Arthritis
|
September 7, 2020 | Phase 4 |
NCT02833350 | Genentech, Inc. |
Rheumatoid Arthritis
|
September 9, 2016 | Phase 2 |
NCT01970475 | Amgen |
Arthritis, Rheumatoid
|
October 2013 | Phase 3 |
NCT00298272 | Biogen|Hoffmann-La Roche|Genentech, Inc. |
Rheumatoid Arthritis
|
May 2006 | Phase 2 |
NCT00646178 | Abbott |
Arthritis|Psoriatic
|
June 2003 | Phase 3 |
NCT01629628 | Tel-Aviv Sourasky Medical Center|Abbott |
Crohn Disease
|
July 2012 | Phase 3 |
NCT01021735 | University of Glasgow|Arthritis Research UK|NHS Lothian|NHS Grampian|NHS Tayside|NHS Borders|NHS Fife |
Rheumatoid Arthritis
|
April 2010 | Phase 4 |
NCT02557100 | Bristol-Myers Squibb |
Rheumatoid Arthritis
|
November 19, 2015 | Phase 4 |
NCT02878083 | Nantes University Hospital|Takeda|Mauna Kea Technologies|Institut National de la Santé Et de la Recherche Médicale, France |
ULCERATIVE COLITIS
|
January 11, 2017 | Not Applicable |
NCT00237887 | Abbott |
Psoriasis
|
December 2004 | Phase 3 |
NCT02450513 | Universitaire Ziekenhuizen KU Leuven |
Crohn´s Disease
|
March 2012 | |
NCT03505008 | Keio University|Eisai Co., Ltd. |
Rheumatoid Arthritis
|
April 18, 2018 | Phase 4 |
NCT01970488 | Amgen |
Psoriasis
|
October 18, 2013 | Phase 3 |
NCT02437253 | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center |
Mucopolysaccharidosis Type I|Mucopolysaccharidosis Type II|Mucopolysaccharidosis Type VI
|
May 2015 | Phase 1|Phase 2 |
NCT05535738 | John Harris|University of Massachusetts, Worcester |
Skin Inflammation|Allergic Contact Dermatitis
|
September 15, 2022 | Phase 2|Phase 3 |
NCT01893996 | Jonathan Graf|American College of Rheumatology Research and Education Foundation|AbbVie|University of California, San Francisco |
Rheumatoid Arthritis|Cardiovascular Disease
|
July 2013 | Phase 4 |
NCT04988308 | Janssen Research & Development, LLC |
Hidradenitis Suppurativa
|
October 12, 2021 | Phase 2 |
NCT01895764 | University Hospital, Tours |
Ankylosing Spondylitis
|
March 2013 | Phase 4 |
NCT02714322 | Mylan Inc.|Mylan GmbH|Viatris Inc. |
Psoriasis|Arthritis, Psoriatic
|
June 2015 | Phase 3 |
NCT02207231 | Janssen Research & Development, LLC |
Psoriasis
|
November 26, 2014 | Phase 3 |
NCT00311246 | University of Chicago|Abbott |
Sarcoidosis
|
April 2006 | Phase 2 |
NCT02634541 | University of Helsinki|AbbVie |
Ankylosing Spondyloarthritis
|
January 2016 | Phase 4 |
NCT03579823 | Alvotech Swiss AG |
Healthy Volunteers
|
May 21, 2018 | Phase 1 |
NCT01088165 | Medical University of Vienna |
Psoriasis|Cardiovascular Diseases|Diabetes Mellitus, Type 2
|
May 2010 | Phase 4 |
NCT00195663 | AbbVie (prior sponsor, Abbott)|AbbVie |
Early Rheumatoid Arthritis
|
December 2000 | Phase 3 |
NCT01465438 | Glostrup University Hospital, Copenhagen|University Hospital, Gentofte, Copenhagen|Copenhagen University Hospital at Herlev|Copenhagen University Hospital, Hvidovre |
Psoriatic Arthritis
|
November 2006 | Phase 4 |
NCT00195676 | Abbott |
Psoriasis
|
May 2004 | Phase 3 |
NCT02668640 | AbbVie |
Rheumatoid Arthritis
|
May 1, 2016 | |
NCT05057273 | Landos Biopharma Inc. |
Crohn´s Disease
|
November 2021 | Phase 2 |
NCT02065622 | AbbVie |
Ulcerative Colitis (UC)
|
March 27, 2014 | Phase 3 |
NCT01163617 | AbbVie (prior sponsor, Abbott)|AbbVie |
Rheumatoid Arthritis
|
May 2010 | Phase 2 |
NCT02374021 | Brigham and Women´s Hospital|Columbia University |
Arthritis, Rheumatoid
|
July 2016 | Phase 4 |
NCT01012570 | Gerhard Rogler|University of Zurich |
Crohn´s Disease
|
August 2009 | |
NCT01270035 | Keio University|Saitama Medical University |
Rheumatoid Arthritis
|
January 2011 | Phase 4 |
NCT05151848 | Chinese SLE Treatment And Research Group |
Takayasu Arteritis
|
January 5, 2022 | Phase 4 |
NCT01064856 | AbbVie (prior sponsor, Abbott)|AbbVie |
Peripheral Spondyloarthritis
|
February 2010 | Phase 3 |
NCT02198651 | AbbVie |
Rheumatoid Arthritis|Musculoskeletal and Connective Tissue Diseases
|
January 5, 2015 | Phase 4 |
NCT04588818 | Sun Yat-sen University |
Uveitis
|
February 1, 2020 | Phase 2 |
NCT04224194 | Alvotech Swiss AG |
RA
|
November 4, 2019 | Phase 3 |
NCT03311464 | AbbVie |
Pyoderma Gangrenosum
|
October 27, 2017 | Phase 3 |
NCT05172817 | Institute for Developing Science and Health Initiatives, Bangladesh|Universal Medical College Hospital, Bangladesh|Green Life Center for Rheumatic Care & Research, Bangladesh|Incepta Pharmaceuticals Ltd, Bangladesh |
Pharmacokinetics|Safety|Efficacy|Rheumatoid Arthritis
|
June 2, 2021 | Phase 2|Phase 3 |
NCT01405326 | The Rheumatological Center of Helsinki|Abbott |
Rheumatoid Arthritis
|
May 2011 | Phase 4 |
NCT00731757 | Wright State University|Stanford University |
Sarcoidosis|Cutaneous Sarcoidosis
|
May 2009 | Phase 2 |
NCT03983876 | Alvotech Swiss AG |
Phase 1
|
July 1, 2019 | Phase 1 |
NCT02141997 | AbbVie |
Rheumatoid Arthritis
|
July 2014 | Phase 2 |
NCT02904902 | AbbVie |
Hidradenitis Suppurativa
|
September 6, 2016 | Phase 3 |
NCT01502423 | AbbVie (prior sponsor, Abbott)|AbbVie |
Rheumatoid Arthritis
|
January 2012 | Phase 2 |
NCT00233571 | Abbott |
Rheumatoid Arthritis
|
June 2000 | Phase 3 |
NCT04230213 | Pfizer |
Rheumatoid Arthritis
|
January 13, 2020 | Phase 3 |
NCT02739828 | AbbVie |
Hidradenitis Suppurativa
|
April 7, 2016 | |
NCT02187055 | Pfizer |
Rhematoid Arthritis
|
August 2014 | Phase 4 |
NCT00645905 | Abbott |
Psoriasis
|
June 2003 | Phase 2 |
NCT00234845 | Abbott |
Rheumatoid Arthritis
|
March 2003 | Phase 3 |
NCT01138657 | AbbVie (prior sponsor, Abbott)|AbbVie |
Uveitis
|
August 2010 | Phase 3 |
NCT04705844 | Ology Bioservices|Pharm-Olam, LLC|Chemical, Biological, Radiological, and Nuclear Medical |
Mild to Moderate COVID-19
|
September 2021 | Phase 3 |
NCT01716039 | Alimentiv Inc.|Abbott |
Ulcerative Colitis
|
June 2013 | Phase 2 |
NCT00448383 | Abbott |
Rheumatoid Arthritis
|
September 2002 | Phase 3 |
NCT02852694 | PIBD-Net|European Commission |
Crohn´s Disease
|
February 28, 2017 | Phase 4 |
NCT00427921 | Abbott |
Crohn´s Disease
|
January 2007 | Phase 3 |
NCT01387815 | AbbVie (prior sponsor, Abbott)|Cato Research|JSS Medical Research Inc.|AbbVie |
Psoriasis
|
August 16, 2011 | |
NCT01382160 | University Hospital, Tours |
Rheumatoid Arthritis
|
January 2011 | Phase 4 |
NCT02994836 | Fundación de Investigación Biomédica - Hospital Universitario de La Princesa |
Crohn´s Disease|Inflammatory Bowel Disease|Ulcerative Colitis
|
April 21, 2017 | Phase 4 |
NCT05527444 | Qilu Hospital of Shandong University |
Ankylosing Spondylitis
|
March 15, 2022 | Phase 4 |
NCT01078571 | Abbott |
Rheumatoid Arthritis
|
May 2006 | |
NCT01185301 | AbbVie (prior sponsor, Abbott)|AbbVie |
Early Rheumatoid Arthritis
|
October 2010 | Phase 3 |
NCT04088409 | Eli Lilly and Company |
Uveitis
|
October 16, 2019 | Phase 3 |
NCT03261102 | waqqas.afif|AbbVie|McGill University Health Centre+Research Institute of the McGill University Health Centre |
Crohn Disease|Drug Monitoring|Inflammatory Bowel Diseases
|
January 17, 2017 | Not Applicable |
NCT00853099 | AbbVie (prior sponsor, Abbott)|Eisai Co., Ltd.|AbbVie |
Ulcerative Colitis
|
February 2009 | Phase 3 |
NCT00645892 | Abbott |
Psoriasis
|
November 2003 | Phase 2 |
NCT00338650 | Abbott |
Crohn´s Disease
|
June 2006 | Phase 3 |
NCT00185562 | Stanford University |
Osteoarthritis
|
June 2005 | Phase 2 |
NCT02167139 | Samsung Bioepis Co., Ltd. |
Rheumatoid Arthritis
|
May 2014 | Phase 3 |
NCT00929864 | Bristol-Myers Squibb |
Rheumatoid Arthritis
|
October 2009 | Phase 3 |
NCT04798755 | Hospital San Carlos, Madrid |
Uveitis
|
January 12, 2022 | Phase 3 |
NCT03220841 | St Vincent´s Hospital Melbourne|Australasian Gastro Intestinal Research Foundation|AbbVie |
Crohn Disease|Inflammatory Bowel Diseases|Stricture; Bowel
|
October 9, 2017 | Phase 4 |
NCT05502731 | Leiden University Medical Center|Galapagos NV |
Rheumatoid Arthritis
|
October 2022 | Phase 4 |
NCT01114880 | Abbott |
Ankylosing Spondylitis
|
January 2010 | Phase 3 |
NCT00048542 | Abbott |
Arthritis, Juvenile Idiopathic
|
September 2002 | Phase 3 |
NCT03561649 | University Hospital, Grenoble|SINNOVIAL |
Spondylitis, Ankylosing
|
June 14, 2018 | Not Applicable |
NCT02814175 | AbbVie |
Psoriatic Arthritis
|
August 5, 2016 | Phase 4 |
NCT02489227 | Coherus Biosciences, Inc. |
Plaque Psoriasis
|
August 2015 | Phase 3 |
NCT01283971 | Hoffmann-La Roche |
Rheumatoid Arthritis
|
May 2011 | Phase 4 |
NCT04551352 | Hoffmann-La Roche |
Cutaneous Melanoma|Uveal Melanoma|Mucosal Melanoma
|
October 28, 2020 | Phase 1 |
NCT03357939 | Shanghai Henlius Biotech |
Immune System Disorder
|
January 12, 2017 | Phase 1 |
NCT02333383 | AbbVie |
Ankylosing Spondylitis
|
December 31, 2014 | |
NCT02330380 | University Hospitals Cleveland Medical Center|National Psoriasis Foundation |
Psoriasis|Inflammation
|
April 2013 | |
NCT02148718 | AbbVie|Laboratorio Echevarne|Pivotal S.L. |
Moderate to Severe Crohn´s Disease
|
June 2014 | Phase 4 |
NCT02035800 | Université de Sherbrooke|AbbVie |
RheumatoId Arthritis
|
May 2013 | Phase 4 |
NCT05590455 | ANRS, Emerging Infectious Diseases |
Tuberculous Meningitis|HIV I Infection
|
December 15, 2022 | Phase 2 |
NCT00650156 | AbbVie |
Rheumatoid Arthritis
|
June 2007 | Phase 1 |
NCT01166282 | AbbVie (prior sponsor, Abbott)|AbbVie |
Enthesitis Related Arthritis (ERA)
|
September 2010 | Phase 3 |
NCT00348283 | Abbott |
Crohn´s Disease
|
August 2006 | Phase 3 |
NCT02629159 | AbbVie |
Rheumatoid Arthritis
|
December 1, 2015 | Phase 3 |
NCT01373151 | CSL Behring |
Rheumatoid Arthritis
|
June 2011 | Phase 2 |
NCT03104400 | AbbVie |
Psoriatic Arthritis
|
April 27, 2017 | Phase 3 |
NCT03100253 | Mario Negri Institute for Pharmacological Research |
Rheumatoid Arthritis
|
March 1, 2018 | Phase 4 |
NCT02539849 | Hospital Universitari Vall d´Hebron Research Institute|AbbVie |
Crohn Disease
|
December 2014 | Not Applicable |
NCT04882683 | Shandong Qilu Stem Cells Engineering Co., Ltd. |
Ulcerative Colitis
|
June 1, 2021 | Not Applicable |
NCT02092467 | Pfizer |
Arthritis, Rheumatoid
|
March 14, 2014 | Phase 4 |
NCT02451748 | University of Illinois at Chicago|UCB Pharma |
Rheumatoid Arthritis
|
August 2015 | Phase 4 |
NCT00855608 | Rafic Hariri University Hospital|American University of Beirut Medical Center |
Uveitis|Diabetic Retinopathy|Choroidal Neovascularization
|
March 2009 | Phase 1 |
NCT00216177 | Hvidovre University Hospital|University Hospital, Gentofte, Copenhagen |
Rheumatoid Arthritis
|
September 2005 | Phase 4 |
NCT03917303 | Maastricht University Medical Center|Maastricht University|ZonMw: The Netherlands Organisation for Health Research and Development |
Crohn Disease|Inflammatory Bowel Diseases
|
December 23, 2019 | Phase 4 |
NCT03153319 | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center |
Mucopolysaccharidosis I|Mucopolysaccharidosis II|Mucopolysaccharidosis VI
|
June 5, 2017 | Phase 1|Phase 2 |
NCT05153200 | Ottawa Hospital Research Institute|The Ottawa Hospital|University of Ottawa |
Rheumatoid Arthritis
|
January 2022 | Phase 4 |
NCT01971970 | Erasmus Medical Center|Merck Sharp & Dohme LLC |
Inflammatory Bowel Diseases
|
October 2013 | |
NCT00195702 | Abbott |
Rheumatoid Arthritis
|
February 2000 | Phase 3 |
NCT00686374 | AbbVie (prior sponsor, Abbott)|AbbVie |
Crohn´s Disease
|
May 1, 2008 | Phase 3 |
NCT00305539 | Assistance Publique - Hôpitaux de Paris|Abbott |
Giant Cell Arteritis
|
May 2006 | Phase 3 |
NCT02196701 | AbbVie |
Psoriasis
|
August 5, 2014 | Phase 3 |
NCT00724672 | Merck Sharp & Dohme LLC |
Rheumatoid Arthritis
|
September 2008 | |
NCT00645814 | Abbott |
Psoriasis
|
March 2003 | Phase 2 |
NCT01872546 | Poitiers University Hospital |
Chronic Plaque Psoriasis
|
Phase 2 | |
NCT00427362 | Abbott |
Psoriatic Arthritis
|
May 2006 | Phase 3 |
NCT00808509 | AbbVie (prior sponsor, Abbott)|Pharma Consulting Group AB|AbbVie |
Arthritis, Rheumatoid
|
January 2009 | Phase 4 |
NCT02497469 | Takeda |
Colitis, Ulcerative
|
June 29, 2015 | Phase 3 |
NCT02696785 | Eli Lilly and Company |
Spondyloarthritis
|
May 2, 2016 | Phase 3 |
NCT00566722 | Abbott |
Psoriasis
|
January 2008 | Phase 3 |
NCT01483599 | Janssen Inc. |
Psoriasis
|
November 10, 2011 | Phase 2 |
NCT02586831 | Camillo Ricordi and Jay Skyler|Diabetes Research Institute Foundation|University of Miami |
Diabetes Mellitus, Type 1|Hypoglycemia|Autoimmune Diseases|Diabetes Mellitus
|
December 1, 2023 | Phase 1|Phase 2 |
NCT00963313 | Dr. FRANCISCO J. BLANCO-GARCIA|Instituto de Investigacion Biomedica de A Coruna |
Psoriatic Arthritis
|
March 2010 | |
NCT00480272 | IRCCS Policlinico S. Matteo |
Rheumatoid Arthritis
|
May 2007 | Phase 4 |
NCT00650026 | Abbott |
Rheumatoid Arthritis
|
||
NCT04154852 | University of Leeds|Abbott |
Oligoarthritis
|
June 2011 | Phase 2 |
NCT00667355 | Abbott|Eisai Co., Ltd. |
Ankylosing Spondylitis
|
February 2008 | Phase 3 |
NCT05626348 | Qilu Hospital of Shandong University |
Arthritis, Rheumatoid
|
December 22, 2021 | Phase 4 |
NCT01029847 | Rigshospitalet, Denmark |
Spondyloarthritis
|
December 2009 | Phase 4 |
NCT01225393 | Genentech, Inc. |
Rheumatoid Arthritis
|
November 2010 | Phase 2 |
NCT01870284 | Eli Lilly and Company |
Spondylitis, Ankylosing
|
July 2014 | Phase 3 |
NCT00445939 | Abbott|Abbott Japan Co.,Ltd|Eisai Co., Ltd. |
Crohn´s Disease
|
February 2007 | Phase 2|Phase 3 |
NCT00690911 | Wake Forest University|Wake Forest University Health Sciences |
Sarcoidosis
|
Phase 2 | |
NCT02565810 | Samsung Bioepis Co., Ltd. |
Rheumatoid Arthritis
|
September 2015 | Phase 2 |
NCT01494857 | Clalit Health Services |
Ulcerative Colitis
|
January 2012 | Phase 3 |
NCT03849313 | Alvotech Swiss AG |
Healthy Volunteers
|
March 20, 2019 | Phase 1 |
NCT03927352 | Sinocelltech Ltd. |
Psoriasis
|
September 5, 2019 | Phase 3 |
NCT04115748 | Gilead Sciences|Galapagos NV |
Psoriatic Arthritis
|
December 3, 2019 | Phase 3 |
NCT01870986 | Pfizer |
Healthy
|
May 2013 | Phase 1 |
NCT02207244 | Janssen Research & Development, LLC |
Psoriasis
|
November 3, 2014 | Phase 3 |
NCT01070303 | Abbott |
Crohn´s Disease
|
August 2002 | Phase 3 |
NCT01592292 | Hoffmann-La Roche |
Rheumatoid Arthritis
|
November 2011 | |
NCT00939003 | AbbVie (prior sponsor, Abbott)|AbbVie |
Axial Spondyloarthritis
|
July 2009 | Phase 3 |
NCT00195715 | Abbott |
Crohn´s Disease
|
September 2004 | Phase 3 |
NCT03412747 | UCB Biopharma SRL|UCB Pharma |
Chronic Plaque Psoriasis|Moderate to Severe Plaque Psoriasis
|
January 26, 2018 | Phase 3 |
NCT00927069 | Innovaderm Research Inc.|Abbott |
Plaque Psoriasis
|
March 2007 | Phase 3 |
NCT01958827 | AbbVie |
Crohn´s Disease
|
September 2013 | Phase 3 |
NCT03172377 | Radboud University Medical Center|Erasmus Medical Center |
Crohn Disease in Remission|Crohn Disease
|
May 3, 2017 | Phase 4 |
NCT00550446 | Pfizer |
Arthritis, Rheumatoid
|
September 2007 | Phase 2 |
NCT01185288 | AbbVie (prior sponsor, Abbott)|AbbVie |
Rheumatoid Arthritis
|
September 2010 | Phase 4 |
NCT02206867 | LG Life Sciences |
Healthy Subjects
|
August 2014 | Phase 1 |
NCT01670240 | Odense University Hospital|University of Southern Denmark|Hvidovre University Hospital|Aarhus University Hospital|AbbVie |
Ulcerative Colitis|Pouchitis
|
August 2012 | Phase 3 |
NCT02912247 | Innovent Biologics (Suzhou) Co. Ltd. |
Healthy
|
October 27, 2016 | Phase 1 |
NCT02171429 | Hoffmann-La Roche |
Ulcerative Colitis
|
November 14, 2014 | Phase 3 |
NCT01136252 | Hospital Universitari Vall d´Hebron Research Institute |
Age-Related Macular Degeneration|Choroidal Neovascularization
|
May 2010 | Phase 2 |
NCT00647920 | Abbott |
Rheumatoid Arthritis
|
July 2003 | Phase 3 |
NCT03180957 | University of Oxford|Department of Health, United Kingdom|Wellcome Trust|180 Therapeutics LP |
Dupuytren´s Disease
|
March 2, 2016 | Phase 2 |
NCT01029613 | Glostrup University Hospital, Copenhagen |
Rheumatoid Arthritis
|
December 2009 | |
NCT05090124 | NHS Greater Glasgow and Clyde|University of Glasgow |
Rheumatoid Arthritis
|
January 1, 2022 | Not Applicable |
NCT03059849 | McMaster University |
Crohn Disease|Ulcerative Colitis
|
February 1, 2018 | Phase 4 |
NCT01468207 | AbbVie (prior sponsor, Abbott)|AbbVie |
Hidradenitis Suppurativa (HS)
|
November 2011 | Phase 3 |
NCT03464136 | Janssen Scientific Affairs, LLC |
Crohn Disease
|
March 29, 2018 | Phase 3 |
NCT04131322 | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla |
Crohn Disease|Ulcerative Colitis
|
October 10, 2019 | Phase 4 |
NCT01609205 | Hamed Rezaei|Abbott|Karolinska Institutet |
Rheumatoid Arthritis
|
October 2012 | Phase 4 |
NCT03414502 | University of Nebraska |
Rheumatoid Arthritis
|
August 2007 | Phase 3 |
NCT03014947 | Fresenius Kabi SwissBioSim GmbH |
Healthy Subjects
|
May 2014 | Phase 1 |
NCT04643483 | UCB Biopharma SRL|UCB Pharma |
Crohn´s Disease
|
June 2021 | Phase 3 |
NCT00796705 | National Institute of Allergy and Infectious Diseases (NIAID) |
Rheumatoid Arthritis
|
November 2008 | Phase 4 |
NCT00409682 | Abbott |
Crohn´s Disease
|
April 2007 | Phase 3 |
NCT04251741 | Reade Rheumatology Research Institute|ZonMw: The Netherlands Organisation for Health Research and Development|Sint Maartenskliniek |
Rheumatoid Arthritis
|
July 31, 2020 | Phase 4 |
NCT02163759 | Hoffmann-La Roche |
Ulcerative Colitis
|
November 4, 2014 | Phase 3 |
NCT00409617 | Abbott |
Crohn´s Disease
|
December 2006 | Phase 3 |
NCT01265823 | AbbVie (prior sponsor, Abbott)|AbbVie |
Psoriasis
|
October 2010 | Phase 4 |
NCT01722214 | Innovaderm Research Inc.|Abbott|Montreal Heart Institute |
Psoriasis|Vascular Inflammation|Coronary Atherosclerosis
|
November 2012 | Phase 4 |
NCT01710358 | Eli Lilly and Company |
Rheumatoid Arthritis
|
October 2012 | Phase 3 |
NCT00235105 | Charite University, Berlin, Germany|Abbott |
Ankylosing Spondylitis
|
March 2005 | Phase 2|Phase 3 |
NCT02871635 | Boehringer Ingelheim |
Crohn Disease
|
September 28, 2016 | Phase 3 |
NCT00686439 | University of Alberta |
Osteoarthritis
|
June 2008 | Phase 1|Phase 2 |
NCT00918255 | Abbott |
Hidradenitis Suppurativa
|
April 2009 | Phase 2 |
NCT05510063 | Samsung Bioepis Co., Ltd.|Organon and Co |
Plaque Psoriasis
|
August 4, 2022 | Phase 4 |
NCT04009668 | University of Michigan |
FSGS|MCD|Focal Segmental Glomerulosclerosis|Minimal Change Disease
|
October 2, 2019 | Phase 2 |
NCT01510548 | Kuopio University Hospital |
Disc Prolapse|Pain
|
March 2007 | Phase 3 |
NCT01148225 | AbbVie |
Uveitis
|
November 23, 2010 | Phase 3 |
NCT01635764 | AbbVie (prior sponsor, Abbott)|AbbVie |
Hidradenitis Suppurativa
|
April 2012 | Phase 3 |
NCT03816397 | Nisha Acharya|Children´s Hospital of Philadelphia|Children´s Hospital Medical Center, Cincinnati|Children´s Mercy Hospital Kansas City|National Eye Institute (NEI)|Great Ormond Street Hospital for Children NHS Foundation Trust|University Hospitals Bristol and Weston NHS Foundation Trust|Alder Hey Children´s NHS Foundation Trust|Seattle Children´s Hospital|Newcastle-upon-Tyne Hospitals NHS Trust|University Hospital Southampton NHS Foundation Trust|Sheffield Children´s NHS Foundation Trust|Children´s Health|Sydney Children´s Hospitals Network|Cambridge University Hospitals NHS Foundation Trust|Johns Hopkins University|Norfolk and Norwich University Hospitals NHS Foundation Trust|Vanderbilt University Medical Center|University of California, Davis|University of Texas at Austin|University of Miami|Spokane Eye Clinical Research|University of California, San Francisco |
Uveitis|JIA
|
March 15, 2020 | Phase 4 |
NCT00573794 | AbbVie (prior sponsor, Abbott)|AbbVie |
Ulcerative Colitis
|
November 28, 2007 | Phase 3 |
NCT05291039 | Rehab Werida|Damanhour University |
Irritable Bowel Disease
|
January 1, 2022 | Not Applicable |
NCT01235689 | AbbVie (prior sponsor, Abbott)|AbbVie |
Crohn´s Disease
|
February 11, 2011 | Phase 3 |
NCT00235820 | Abbott |
Psoriasis
|
July 2005 | Phase 3 |
NCT02808975 | AbbVie |
Hidradenitis Suppurativa (HS)
|
July 18, 2016 | Phase 4 |
NCT01736189 | AbbVie (prior sponsor, Abbott)|AbbVie |
Rheumatoid Arthritis
|
October 11, 2012 | |
NCT03172325 | Cinnagen |
Active Rheumatoid Arthritis
|
November 18, 2015 | Phase 3 |
NCT02499783 | AbbVie |
Crohn´s Disease
|
August 17, 2015 | Phase 3 |
NCT04610476 | University of Erlangen-Nürnberg Medical School |
Psoriatic Arthritis|Withdrawal|Reduction
|
October 19, 2020 | Phase 3 |
NCT00055523 | Abbott |
Crohn´s Disease
|
April 2002 | Phase 2 |
NCT00420927 | Abbott |
Rheumatoid Arthritis
|
December 2006 | Phase 4 |
NCT02744755 | Sandoz|Hexal AG |
Rheumatoid Arthritis
|
March 31, 2016 | Phase 3 |
NCT02581345 | Momenta Pharmaceuticals, Inc. |
Chronic Plaque Psoriasis|Psoriasis
|
September 2015 | Phase 3 |
NCT05155592 | Dan Liang|Sun Yat-sen University |
Uveitis|Adalimumab
|
January 1, 2021 | Phase 2 |
NCT05073315 | Amgen |
Plaque Psoriasis
|
October 4, 2021 | Phase 3 |
NCT02019472 | Janssen Research & Development, LLC|GlaxoSmithKline |
Arthritis, Rheumatoid
|
April 4, 2014 | Phase 3 |
NCT05164198 | Hanyang University Seoul Hospital|Linical Korea |
Ankylosing Spondylitis|Axial Spondyloarthritis
|
January 15, 2022 | Phase 4 |
NCT05372939 | Applied Molecular Transport |
Ulcerative Colitis
|
February 5, 2021 | Phase 2 |
NCT01468233 | AbbVie (prior sponsor, Abbott)|AbbVie |
Hidradenitis Suppurativa (HS)
|
November 2011 | Phase 3 |
NCT00195819 | Abbott |
Ankylosing Spondylitis
|
December 2003 | Phase 3 |
NCT01704599 | Wayne State University|Abbott |
Psoriasis
|
January 2009 | Phase 1|Phase 2 |
NCT01000441 | University Hospital, Strasbourg, France |
Rheumatoid Arthritis
|
December 23, 2009 | Phase 4 |
NCT05495568 | Celltrion |
Moderate to Severe Chronic Plaque Psoriasis
|
November 16, 2022 | Phase 3 |
NCT01657513 | University Hospital, Gentofte, Copenhagen|The Michaelsen Foundation|Pfizer |
Psoriasis
|
June 2012 | Not Applicable |
NCT03970824 | Celltrion |
Healthy
|
May 31, 2019 | Phase 1 |
NCT00647400 | Abbott|Abbott Japan Co.,Ltd|Eisai Co., Ltd. |
Psoriasis
|
April 2006 | Phase 2|Phase 3 |
NCT01338740 | University Hospital, Ghent|Abbott |
Crohn´s Disease
|
April 2011 | |
NCT01644396 | AbbVie (prior sponsor, Abbott)|AbbVie |
Moderate to Severe Plaque Psoriasis
|
May 2012 | Phase 4 |
NCT01295151 | Julia Brown|University of Leeds |
Rheumatoid Arthritis
|
August 2011 | Phase 4 |
NCT02750800 | AbbVie |
Rheumatoid Arthritis|Ankylosing Spondylitis|Psoriatic Arthritis|Psoriasis|Crohn´s Disease|Ulcerative Colitis
|
April 7, 2016 | |
NCT00077779 | Abbott |
Crohn´s Disease
|
July 2003 | Phase 3 |
NCT00133315 | Hvidovre University Hospital |
Spondylarthropathies|Ankylosing Spondylitis|Psoriatic Arthritis
|
September 2004 | Phase 4 |
NCT00783510 | AbbVie |
Juvenile Idiopathic Arthritis|JIA
|
July 11, 2008 | |
NCT02016482 | AbbVie |
Nail Psoriasis|Plaque Psoriasis
|
January 2014 | Phase 3 |
NCT02256462 | Schneider Children´s Medical Center, Israel |
Crohn´s Disease
|
May 1, 2015 | Phase 4 |
NCT03651518 | Assistance Publique - Hôpitaux de Paris |
Inflammatory Disease|Autoimmune Diseases
|
October 20, 2020 | Phase 2 |
NCT01752855 | AbbVie (prior sponsor, Abbott)|AbbVie |
Rheumatoid Arthritis
|
December 2012 | Phase 2 |
NCT00646386 | Abbott |
Arthritis|Psoriatic
|
March 2003 | Phase 2 |
NCT04131504 | Children´s Hospital Medical Center, Cincinnati|The Leona M. and Harry B. Helmsley Charitable Trust |
Crohn´s Disease|IBD
|
October 16, 2019 | |
NCT04194827 | Reade Rheumatology Research Institute|ZonMw: The Netherlands Organisation for Health Research and Development|Sint Maartenskliniek |
Rheumatoid Arthritis
|
March 1, 2020 | Phase 4 |
NCT03306446 | Groupe d´Etude Therapeutique des Affections Inflammatoires Digestives |
CD
|
March 17, 2015 | Phase 4 |
NCT00696059 | Hvidovre University Hospital|Abbott |
Rheumatoid Arthritis|Arthritis|Joint Diseases
|
August 2004 | Phase 4 |
NCT03217734 | Jeffrey J Crowley MD|AbbVie|Bakersfield Dermatology & Skin Cancer Medical Group |
Psoriasis
|
April 10, 2017 | Phase 2|Phase 3 |
NCT05313620 | Fundación de Investigación Biomédica - Hospital Universitario de La Princesa |
Ulcerative Colitis|Thromboembolism
|
April 1, 2022 | Phase 4 |
NCT03895203 | UCB Biopharma SRL|UCB Pharma |
Psoriatic Arthritis
|
April 3, 2019 | Phase 3 |
NCT01162421 | AbbVie (prior sponsor, Abbott)|Mount Sinai Hospital, Canada|AbbVie |
Rheumatoid Arthritis
|
September 2010 | Phase 4 |
NCT02332590 | Sanofi|Regeneron Pharmaceuticals |
Rheumatoid Arthritis
|
January 28, 2015 | Phase 3 |
NCT03739853 | University of Oxford |
Psoriatic Arthritis
|
May 14, 2019 | Phase 4 |
NCT02185014 | AbbVie |
Crohn´s Disease
|
August 12, 2014 | Phase 3 |
NCT04003922 | Assistance Publique Hopitaux De Marseille |
Rasmussen Encephalitis
|
October 20, 2020 | |
NCT01866592 | University of Pennsylvania|AbbVie |
Psoriasis|Cardiovascular Disease
|
April 2013 | Phase 4 |
NCT00649922 | Abbott |
Rheumatoid Arthritis
|
October 2003 | Phase 4 |
NCT01553058 | University of Pennsylvania |
Psoriasis|Cardiovascular Disease
|
July 2012 | Phase 4 |
NCT03828019 | JHSPH Center for Clinical Trials |
Uveitis
|
September 17, 2019 | Phase 3 |
NCT01793519 | Georgetown University|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|University of Maryland, College Park|Washington D.C. Veterans Affairs Medical Center|Medstar Health Research Institute|Patient-Centered Outcomes Research Institute|Arthritis and Pain Associates of PG County|Arthritis & Rheumatism Associates, P.C.|Rheumatology Associates of Baltimore, L.L.C.|The Arthritis Clinic of Northern Virginia, P.C.|Arthritis and Rheumatic Disease Associates, P.C. |
Rheumatoid Arthritis
|
January 2013 | Phase 4 |
NCT01181570 | Innovaderm Research Inc.|Abbott |
Psoriasis|Sleep Apnea, Obstructive
|
September 2010 | Phase 4 |
NCT00085644 | Abbott |
Ankylosing Spondylitis
|
January 2004 | Phase 3 |
NCT05322473 | MoonLake Immunotherapeutics AG |
Hidradenitis Suppurativa
|
April 25, 2022 | Phase 2 |
NCT01646073 | AbbVie (prior sponsor, Abbott)|AbbVie |
Plaque Psoriasis
|
August 2012 | Phase 3 |
NCT02132234 | Jagiellonian University|Departmet of Rheumatology, J Dietl Hospital, Krakow, Poland |
Rheumatoid Arthritis|Psoriatic Arthritis|Ankylosing Spondylitis|Hypertension
|
June 2013 | Phase 4 |
NCT02065570 | AbbVie |
Crohn´s Disease
|
May 1, 2014 | Phase 3 |
NCT02533375 | AbbVie |
Generalized Pustular Psoriasis (GPP)|Adalimumab|Japanese
|
September 28, 2015 | Phase 3 |
NCT02963402 | Fundació Institut de Recerca de l´Hospital de la Santa Creu i Sant Pau |
Arthritis,Rheumatoid
|
November 9, 2016 | |
NCT00932113 | Tufts Medical Center |
Psoriasis
|
June 2009 | Phase 4 |
NCT01674413 | Peter Higgins|AbbVie|University of Michigan |
Crohn´s Disease
|
October 2013 | Phase 3 |
NCT00512863 | Abbott |
Asthma
|
August 2007 | Phase 2 |
NCT03662919 | Biogen |
Arthritis, Rheumatoid|Spondylitis, Ankylosing|Arthritis, Psoriatic|Crohn´s Disease|Colitis, Ulcerative
|
July 2, 2018 | |
NCT00837434 | National Institute of Allergy and Infectious Diseases (NIAID)|Autoimmunity Centers of Excellence|Rho Federal Systems Division, Inc. |
Rheumatoid Arthritis
|
March 2009 | Phase 4 |
NCT05590416 | Tianjin Medical University |
Vogt-Koyanagi-Harada Disease|Adalimumab
|
June 1, 2021 | |
NCT00517296 | Vanderbilt University Medical Center |
Crohn Disease|Rectal Fistula
|
January 2008 | Phase 4 |
NCT01564823 | Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa|Effice Servicios Para la Investigacion S.L. |
Crohn´s Disease
|
June 2012 | Phase 3 |
NCT02349451 | AbbVie |
Psoriatic Arthritis
|
April 28, 2015 | Phase 2 |
NCT00235885 | Abbott |
Psoriatic Arthritis
|
July 2005 | Phase 3 |
NCT02706704 | American University of Beirut Medical Center |
Uveitis|Non-Infectious Uveitis
|
February 2016 | Phase 2 |
NCT00597623 | Assistance Publique - Hôpitaux de Paris|Abbott |
Hand Osteoarthritis
|
January 2008 | Phase 3 |
NCT00761514 | Abbott |
Rheumatoid Arthritis
|
November 2006 | Phase 4 |
NCT00234897 | Abbott |
Rheumatoid Arthritis
|
August 2004 | Phase 4 |
NCT00470509 | University Hospital, Geneva |
Sciatica
|
May 2005 | Phase 2 |
NCT04135508 | Bio-Thera Solutions |
Ankylosing Spondylitis
|
December 13, 2016 | Phase 3 |
NCT01270087 | Skane University Hospital|Abbott|The Swedish Research Council|The Swedish Rheumatism Ass|Crafoord Foundation |
Rheumatoid Arthritis
|
May 2005 | Phase 4 |
NCT00940862 | Innovaderm Research Inc.|Abbott|Montreal Heart Institute |
Psoriasis|Vascular Inflammation|Coronary Atherosclerosis
|
July 2009 | Phase 4 |
NCT01695239 | Eli Lilly and Company |
Psoriasis, Arthritic
|
December 2012 | Phase 3 |
NCT00775437 | AbbVie (prior sponsor, Abbott)|AbbVie |
Juvenile Idiopathic Arthritis
|
March 2009 | Phase 3 |
NCT05427942 | Celltrion HealthCare France |
Rheumatoid Arthritis|Ankylosing Spondylarthritis|Axial Spondyloarthritis Without Radiographic Evidence of Ankylosing Spondylitis|Psoriatic Arthritis|Crohn Disease|Ulcerative Colitis
|
June 3, 2022 | |
NCT00538902 | Abbott |
Rheumatoid Arthritis
|
August 2007 | Phase 2|Phase 3 |
NCT05015335 | Peking Union Medical College Hospital |
Uveitis, Anterior|Adalimumab
|
August 19, 2021 | Phase 4 |
NCT03737708 | Astellas Pharma Korea, Inc.|Astellas Pharma Inc |
Rheumatoid Arthritis (RA)
|
February 13, 2019 | Phase 4 |
NCT04909801 | Bristol-Myers Squibb |
Rheumatoid Arthritis
|
September 15, 2021 | Phase 3 |
NCT04453137 | Alvotech Swiss AG |
Plaque Psoriasis
|
June 30, 2020 | Phase 3 |
NCT03248531 | UCB Biopharma SRL|UCB Pharma |
Hidradenitis Suppurativa
|
September 22, 2017 | Phase 2 |
NCT02395055 | Biocad |
Healthy
|
June 2015 | Phase 1 |
NCT00234936 | Abbott |
Rheumatoid Arthritis
|
December 2003 | Phase 3 |
NCT03151551 | Eli Lilly and Company |
Psoriatic Arthritis
|
August 24, 2017 | Phase 4 |
NCT02889796 | Gilead Sciences|Galapagos NV |
Rheumatoid Arthritis
|
August 30, 2016 | Phase 3 |
NCT03619876 | Columbia University|Bristol-Myers Squibb |
Rheumatoid Arthritis|Myocardial Inflammation
|
July 10, 2019 | Phase 4 |
NCT01078610 | Abbott |
Psoriatic Arthritis
|
||
NCT01124838 | AbbVie (prior sponsor, Abbott)|AbbVie |
Uveitis
|
August 2010 | Phase 3 |
NCT00513370 | Abbott |
Psoriasis
|
September 2007 | Phase 3 |
NCT02322008 | Regionshospitalet Viborg, Skive |
Crohn´s Disease|Ulcerative Colitis|Inflammatory Bowel Disease
|
September 2009 | |
NCT02016105 | Sandoz|Hexal AG |
Plaque Type Psoriasis
|
December 2013 | Phase 3 |
NCT00049751 | Abbott |
Rheumatoid Arthritis
|
September 2002 | Phase 3 |
NCT02015793 | AbbVie |
Crohn´s Disease
|
December 2013 | Phase 2 |
NCT02694523 | AbbVie|Boehringer Ingelheim |
Psoriasis
|
March 2016 | Phase 3 |
NCT00348153 | Heidelberg University|Abbott |
Uveitis
|
August 2006 | Phase 2|Phase 3 |
NCT03016260 | TcLand Expression S.A.|European Commission |
RheumatoId Arthritis
|
December 2016 | |
NCT02092961 | AstraZeneca |
Rheumatoid Arthritis
|
February 2011 | Phase 2 |
NCT01251614 | AbbVie (prior sponsor, Abbott)|AbbVie |
Plaque Psoriasis
|
December 2010 | Phase 3 |
NCT01144156 | Rabin Medical Center|Abbott |
Crohn´s Disease
|
Not Applicable | |
NCT01706692 | Swiss Dermatology Network for Targeted Therapies |
Psoriasis
|
July 2011 | |
NCT04089514 | Biogen |
Arthritis, Rheumatoid (RA)|Axial Spondyloarthritis (axSpA)|Arthritis, Psoriatic (PsA)|Crohn´s Disease (CD)|Colitis, Ulcerative (UC)
|
June 30, 2019 | |
NCT01764997 | Sanofi|Regeneron Pharmaceuticals |
Rheumatoid Arthritis
|
April 2013 | Phase 3 |
NCT02897115 | AbbVie|IST GmbH, Germany|Hannover Medical School|Improvement by Movement GmbH, Germany |
Axial Spondyloarthritis
|
September 12, 2016 | Phase 4 |
NCT00195650 | Abbott |
Rheumatoid Arthritis
|
July 2000 | Phase 3 |
NCT01561313 | AbbVie (prior sponsor, Abbott)|AbbVie |
Rheumatoid Arthritis
|
March 2012 | Phase 2 |
NCT00814255 | NYU Langone Health|University of Michigan|The Cleveland Clinic|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
Focal Segmental Glomerulosclerosis
|
December 2008 | Phase 2 |
NCT00445432 | Abbott|Eisai Co., Ltd. |
Crohn´s Disease
|
March 2007 | Phase 2|Phase 3 |
NCT02840175 | Assistance Publique - Hôpitaux de Paris |
Juvenile Idiopathic Arthritis
|
May 18, 2017 | Phase 3 |
NCT02056184 | University of Leeds|AbbVie|Theorem |
Rheumatoid Arthritis|Targeted Ultrasound
|
December 2013 | Phase 4 |
NCT02929251 | Assistance Publique - Hôpitaux de Paris |
Uveitis|Biotherapy
|
June 28, 2017 | Phase 2 |
NCT02632175 | AbbVie |
Ulcerative Colitis
|
November 26, 2015 | Phase 3 |
NCT02760407 | R-Pharm International, LLC|Quintiles, Inc.|OCT Clinical Trials|R-Pharm |
Rheumatoid Arthritis
|
May 24, 2016 | Phase 3 |
NCT00660647 | University of Aarhus|Abbott|Meda Pharmaceuticals|Aarhus University Hospital |
Arthritis, Rheumatoid
|
September 2007 | Phase 3 |
NCT00234884 | Abbott |
Rheumatoid Arthritis
|
September 2003 | |
NCT00105300 | Abbott |
Crohn´s Disease
|
October 2004 | Phase 3 |
NCT01320293 | University of North Carolina, Chapel Hill|AbbVie |
Psoriasis
|
March 2011 | Not Applicable |
NCT00193648 | Northwell Health|University of North Carolina|The Cleveland Clinic |
Focal Glomerulosclerosis
|
July 2005 | Phase 1 |
NCT01505491 | Boehringer Ingelheim |
Healthy
|
December 1, 2011 | Phase 1 |
NCT04171414 | Celltrion|PPD |
Rheumatoid Arthritis
|
September 9, 2019 | Phase 3 |
NCT02113904 | Assistance Publique - Hôpitaux de Paris |
Netherton Syndrome
|
January 27, 2014 | Phase 2 |
NCT02492217 | Universidade Nova de Lisboa |
Ankylosing Spondylitis
|
May 2015 | Phase 4 |
NCT01550965 | AbbVie (prior sponsor, Abbott)|AbbVie |
Ulcerative Colitis
|
May 2012 | Phase 3 |
NCT00574249 | Abbott |
Chronic Plaque Psoriasis
|
November 2007 | Phase 3 |
NCT01768858 | AbbVie|Raffeiner GmbH |
Rheumatoid Arthritis|Ankylosing Spondylitis|Psoriatic Arthritis|Crohn´s Disease|Ulcerative Colitis|Plaque Psoriasis
|
February 5, 2013 | |
NCT02878161 | Fen Li|Central South University |
Rheumatoid Arthritis
|
January 2016 | Phase 4 |
NCT00234234 | University Hospital, Rouen |
Rheumatoid Arthritis
|
January 2006 | Phase 4 |
NCT03316781 | Shanghai Henlius Biotech |
Plaque Psoriasis
|
October 27, 2017 | Phase 3 |
NCT04183608 | Groupe d´Etude Therapeutique des Affections Inflammatoires Digestives|AbbVie |
Ulcerative Colitis
|
January 14, 2020 | Phase 4 |
NCT04527380 | Eli Lilly and Company |
Juvenile Psoriatic Arthritis|Enthesitis Related Arthritis
|
April 13, 2021 | Phase 3 |
NCT00235833 | Abbott|Abbott Japan Co.,Ltd|Eisai Co., Ltd. |
Rheumatoid Arthritis
|
June 2003 | Phase 2 |
NCT00650390 | Abbott |
Rheumatoid Arthritis
|
||
NCT02764762 | Takeda |
Crohn Disease
|
June 12, 2017 | Phase 4 |
NCT04404517 | Hospital Universitario La Paz |
Inflammatory Bowel Diseases
|
October 1, 2019 | Phase 3 |
NCT03823391 | AbbVie |
Rheumatoid Arthritis (RA)
|
March 27, 2019 | Phase 2 |
NCT04300686 | Shanghai Zhongshan Hospital |
Takayasu Arteritis|Tocilizumab|Adalimumab|Treatment
|
March 1, 2020 | Phase 4 |
NCT04222920 | Reade Rheumatology Research Institute|ZonMw: The Netherlands Organisation for Health Research and Development|Sint Maartenskliniek |
Rheumatoid Arthritis
|
March 1, 2020 | Phase 4 |
NCT00690573 | Abbott|Eisai Co., Ltd. |
Juvenile Rheumatoid Arthritis
|
May 2008 | Phase 3 |
NCT00646191 | Abbott |
Psoriasis
|
March 2003 | Phase 2 |
NCT02393378 | Takeda |
Rheumatoid Arthritis
|
April 8, 2015 | Phase 2 |
NCT00647270 | Abbott |
Rheumatoid Arthritis
|
December 2007 | Phase 3 |
NCT00421642 | Mayo Clinic |
Ulcerative Colitis
|
October 2006 | Phase 1 |
NCT01556672 | Innovaderm Research Inc.|Abbott |
Plaque Psoriasis|Crohn´s Disease
|
April 2012 | Phase 4 |
NCT02252809 | Brugmann University Hospital |
Innate Immunity
|
November 2008 | Early Phase 1 |
NCT01812954 | Jochen Schmitt.|Merck Sharp & Dohme LLC|Technische Universität Dresden |
Psoriasis
|
March 2013 | |
NCT00408629 | Abbott |
Ulcerative Colitis
|
November 2006 | Phase 3 |
NCT02516774 | Gustave Roussy, Cancer Campus, Grand Paris |
Anaplastic Thyroid Cancers
|
December 2014 | Phase 1 |
NCT05108259 | Prestige Biopharma Limited |
Healthy Volunteers
|
March 30, 2022 | Phase 1 |
NCT02893254 | Innovent Biologics (Suzhou) Co. Ltd. |
AS
|
September 22, 2016 | Phase 3 |
NCT02097264 | Novo Nordisk A+S |
Inflammation|Rheumatoid Arthritis
|
September 2014 | Phase 2 |
NCT00649545 | Abbott |
Rheumatoid Arthritis
|
||
NCT00690846 | Wake Forest University Health Sciences |
Pyoderma Gangrenosum
|
July 2007 | Phase 2 |
NCT04646187 | University Medical Center Groningen|European Crohn´s and Colitis Organisation|Bühlmann Laboratories AG |
Inflammatory Bowel Diseases|Crohn Disease|Colitis, Ulcerative
|
March 11, 2021 | Phase 4 |
NCT02065557 | AbbVie |
Ulcerative Colitis
|
October 13, 2014 | Phase 3 |
NCT00478660 | Abbott |
Ankylosing Spondylitis
|
February 2006 | Phase 3 |
NCT01497717 | Rambam Health Care Campus|Abbott |
Arthritis; Behcet
|
July 2013 | Phase 3 |
NCT02927353 | Meiji Seika Pharma Co., Ltd. |
Healthy Volunteer
|
August 2016 | Phase 1 |
Liquid
Shipping with dry ice.
Please store the product under the recommended conditions in the Certificate of Analysis.
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.